# A Study of Ramucirumab (LY3009806) in Healthy Participants

> **NCT04495478** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ramucirumab - IV
- **DRUG:** Placebo - IV
- **DRUG:** Ramucirumab - SC
- **DRUG:** Placebo - SC

## Key facts

- **NCT ID:** NCT04495478
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-30
- **Primary completion:** 2021-05-09
- **Final completion:** 2021-05-09
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04495478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04495478, "A Study of Ramucirumab (LY3009806) in Healthy Participants". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04495478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*